Literature DB >> 19713082

Reduced cerebrospinal fluid and plasma nerve growth factor in drug-naïve psychotic patients.

Anvita Kale1, Sadhana Joshi, Anilkumar Pillai, Nilesh Naphade, Msvk Raju, Henry Nasrallah, Sahebarao P Mahadik.   

Abstract

Impaired expression and function of several major neurotrophic factors such as nerve growth factor (NGF) has been proposed to contribute to the neurodevelopmental pathology of schizophrenia. However, the evidence in the majority of studies is based on variable and inconsistent levels of plasma NGF in diverse populations of early psychosis or medicated patients with chronic schizophrenia. We report here the first study comparing NGF levels in cerebrospinal fluid (CSF) and plasma from a unique patient cohort (unmedicated, early psychotic patients with similar racial and dietary patterns) and matched healthy controls. Significantly lower levels of NGF in both CSF (p=0.038) and plasma (p=0.002) were observed in drug-naïve first-episode psychosis patients as compared to controls. The levels of NGF in the CSF correlated (p=0.05) to the plasma values in controls. The data on plasma NGF confirm the reported deficits of NGF in drug-naïve first-episode psychosis. The reduced levels first time observed here may have important implications to repeatedly reported neurobiological and clinical deficits which are discussed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19713082     DOI: 10.1016/j.schres.2009.07.022

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  4 in total

Review 1.  Cerebrospinal fluid biomarker candidates of schizophrenia: where do we stand?

Authors:  Nenad Vasic; Bernhard J Connemann; Robert C Wolf; Hayrettin Tumani; Johannes Brettschneider
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-12-16       Impact factor: 5.270

2.  A meta-analysis of peripheral blood nerve growth factor levels in patients with schizophrenia.

Authors:  X-Y Qin; H-T Wu; C Cao; Y P Loh; Y Cheng
Journal:  Mol Psychiatry       Date:  2017-01-10       Impact factor: 15.992

3.  Cerebrospinal fluid neuroplasticity-associated protein levels in patients with psychiatric disorders: a multiplex immunoassay study.

Authors:  Shinsuke Hidese; Kotaro Hattori; Daimei Sasayama; Takuya Tsumagari; Tomoko Miyakawa; Ryo Matsumura; Yuuki Yokota; Ikki Ishida; Junko Matsuo; Sumiko Yoshida; Miho Ota; Hiroshi Kunugi
Journal:  Transl Psychiatry       Date:  2020-05-21       Impact factor: 6.222

4.  Neuro-Immune Aspects of Schizophrenia with Severe Negative Symptoms: New Diagnostic Markers of Disease Phenotype.

Authors:  I K Malashenkova; V L Ushakov; N V Zakharova; S A Krynskiy; D P Ogurtsov; N A Hailov; E I Chekulaeva; A Y Ratushnyy; S I Kartashov; G P Kostyuk; N A Didkovsky
Journal:  Sovrem Tekhnologii Med       Date:  2021-12-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.